Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 4 trial of RegenoGel-OSP and RegenoGel for knee osteoarthritis
MOH_2017-09-26_000534Phase 4Not yet recruiting
- Sponsor
- ProCore
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in knee osteoarthritis (OA) comparing RegenoGel-OSP, RegenoGel and Placebo (3 arms). Primary endpoint: Pain and daily function. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
RegenoGel-OSPRegenoGel
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on MOH_2017-09-26_000534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-26_000534.